Walter J. Koch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Walter J. Koch has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Robert J. Lefkowitz
Department of Medicine and Biochemistry, Duke University Medical Center and Howard Hughes Medical Institute, Durham, NC, 27710, USA
7 shared publicationsAndrea D. Eckhart
6 shared publicationsDavid C. White
From the Departments of General and Thoracic Surgery (A.S.S., D.C.W., S.E., A.P.K., R.E.L., D.D.G., W.J.K.) and Medicine and Biochemistry (K.W., R.J.K.) and the Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC
6 shared publicationsDonald D. Glower
From the Departments of General and Thoracic Surgery (A.S.S., D.C.W., S.E., A.P.K., R.E.L., D.D.G., W.J.K.) and Medicine and Biochemistry (K.W., R.J.K.) and the Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC
6 shared publications- Ashish S. Shah
Department of Cardiac Surgery, Vanderbilt University Medical Center, Vanderbilt Medical Center East, 1215 21st Ave S, Ste 5025, Nashville, TN 37232
5 shared publications Alan P. Kypson
From the Departments of General and Thoracic Surgery (A.S.S., D.C.W., S.E., A.P.K., R.E.L., D.D.G., W.J.K.) and Medicine and Biochemistry (K.W., R.J.K.) and the Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC
4 shared publications
Latest Publications
- 31 August 2007
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 13 (6) , S144-S145
Darbepoetin Alpha and Insulin-Like Growth Factor-1 Protect the Rat Myocardium Against Myocardial Infarction and Lead To Enhance Angiogenesis
- 31 August 2007
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 13 (6) , S144-S145
Darbepoetin Alpha and Insulin-Like Growth Factor-1 Protect the Rat Myocardium Against Myocardial Infarction and Lead To Enhance Angiogenesis
- 1 January 2004
- Published by Springer Nature
- p. 345-367
Transgenic Mouse Models of Cardiovascular Function and Disease
- 1 January 2004
- Published by Springer Nature
- p. 345-367
Transgenic Mouse Models of Cardiovascular Function and Disease
- Open Access
- 1 August 2003
- Published by Elsevier in Molecular Therapy
- Vol. 8 (2) , 306-313
Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate
- 1 August 2003
- Published by Elsevier in Molecular Therapy
- Vol. 8 (2) , 306-313
Open AccessCatheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate
- 1 August 2003
- Published by Springer Nature in Nature Medicine
- Vol. 9 (8) , 993-994
Sealing the leak, healing the heart
- 1 August 2003
- Published by Springer Nature in Nature Medicine
- Vol. 9 (8) , 993-994
Sealing the leak, healing the heart
- 1 December 2002
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 124 (6) , 1149-1156
Heterotopic transplantation as a model to study functional recovery of unloaded failing hearts
- 1 December 2002
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 124 (6) , 1149-1156
Heterotopic transplantation as a model to study functional recovery of unloaded failing hearts
- 1 June 2002
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 34 (6) , 669-677
Inhibition of βARK1 Restores Impaired Biochemical β-Adrenergic Receptor Responsiveness but does not Rescue CREBA133 Induced Cardiomyopathy
- 1 June 2002
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 34 (6) , 669-677
Inhibition of βARK1 Restores Impaired Biochemical β-Adrenergic Receptor Responsiveness but does not Rescue CREBA133 Induced Cardiomyopathy
- Open Access
- 1 January 2002
- Published by Elsevier in Molecular Therapy
- Vol. 5 (1) , 74-79
Expression of a β-Adrenergic Receptor Kinase Inhibitor Reverses Dysfunction in Failing Cardiomyocytes
- 1 January 2002
- Published by Elsevier in Molecular Therapy
- Vol. 5 (1) , 74-79
Open AccessExpression of a β-Adrenergic Receptor Kinase Inhibitor Reverses Dysfunction in Failing Cardiomyocytes
- 23 October 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (17) , 2069-2074
Ventricular Dysfunction After Cardioplegic Arrest Is Improved After Myocardial Gene Transfer of a β-Adrenergic Receptor Kinase Inhibitor
Background Acute cardiac contractile dysfunction is common after cardiopulmonary bypass (CPB). A potential molecular mechanism is enhanced β-adrenergic receptor kinase (βARK1) activity, because β-adrenergic receptor (βAR) signaling is altered in cardiomyocytes after cardioplegia. Therefore, we examined whether adenovirus-mediated intracoronary delivery of a βARK1 inhibitor (Adv-βARKct) could prevent post-CPB dysfunction. Methods and Results Rabbits were randomized to receive 5×10 11 total viral particles of Adv-βARKct or PBS. After 5 days, hearts were arrested with University of Wisconsin solution, excised, and stored at 4°C for 15 minutes or 4 hours before reperfusion on a Langendorff apparatus. Left ventricular (LV) function measured by end-diastolic pressure response to preload augmentation, contractility (LV dP/dt max ), and relaxation (LV dP/dt min ) was assessed by use of increasing doses of isoproterenol and compared with a control group of nonarrested hearts acutely perfused on the Langendorff apparatus. In the PBS-treated hearts, LV function decreased in a temporal manner and was significantly impaired compared with control hearts after 4 hours of cardioplegic arrest. LV function in Adv-βARKct-treated hearts, however, was significantly enhanced compared with PBS treatment and was similar to control nonarrested hearts even after 4 hours of cardioplegia. Biochemically, several aspects of βAR signaling were dysfunctional in PBS-treated hearts, whereas they were normalized in βARKct-overexpressing hearts. Conclusions Myocardial gene transfer of Adv-βARKct stabilizes βAR signaling and prevents LV dysfunction induced by prolonged cardioplegic arrest. Thus, βARK1 inhibition may represent a novel target in limiting depressed ventricular function after CPB.
- 23 October 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 104 (17) , 2069-2074
Ventricular Dysfunction After Cardioplegic Arrest Is Improved After Myocardial Gene Transfer of a β-Adrenergic Receptor Kinase Inhibitor
Background Acute cardiac contractile dysfunction is common after cardiopulmonary bypass (CPB). A potential molecular mechanism is enhanced β-adrenergic receptor kinase (βARK1) activity, because β-adrenergic receptor (βAR) signaling is altered in cardiomyocytes after cardioplegia. Therefore, we examined whether adenovirus-mediated intracoronary delivery of a βARK1 inhibitor (Adv-βARKct) could prevent post-CPB dysfunction. Methods and Results Rabbits were randomized to receive 5×10 11 total viral particles of Adv-βARKct or PBS. After 5 days, hearts were arrested with University of Wisconsin solution, excised, and stored at 4°C for 15 minutes or 4 hours before reperfusion on a Langendorff apparatus. Left ventricular (LV) function measured by end-diastolic pressure response to preload augmentation, contractility (LV dP/dt max ), and relaxation (LV dP/dt min ) was assessed by use of increasing doses of isoproterenol and compared with a control group of nonarrested hearts acutely perfused on the Langendorff apparatus. In the PBS-treated hearts, LV function decreased in a temporal manner and was significantly impaired compared with control hearts after 4 hours of cardioplegic arrest. LV function in Adv-βARKct-treated hearts, however, was significantly enhanced compared with PBS treatment and was similar to control nonarrested hearts even after 4 hours of cardioplegia. Biochemically, several aspects of βAR signaling were dysfunctional in PBS-treated hearts, whereas they were normalized in βARKct-overexpressing hearts. Conclusions Myocardial gene transfer of Adv-βARKct stabilizes βAR signaling and prevents LV dysfunction induced by prolonged cardioplegic arrest. Thus, βARK1 inhibition may represent a novel target in limiting depressed ventricular function after CPB.
- 6 March 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (9) , 1311-1316
In Vivo Ventricular Gene Delivery of a β-Adrenergic Receptor Kinase Inhibitor to the Failing Heart Reverses Cardiac Dysfunction
Background —Genetic manipulation to reverse molecular abnormalities associated with dysfunctional myocardium may provide novel treatment. This study aimed to determine the feasibility and functional consequences of in vivo β-adrenergic receptor kinase (βARK1) inhibition in a model of chronic left ventricular (LV) dysfunction after myocardial infarction (MI). Methods and Results —Rabbits underwent ligation of the left circumflex (LCx) marginal artery and implantation of sonomicrometric crystals. Baseline cardiac physiology was studied 3 weeks after MI; 5×10 11 viral particles of adenovirus was percutaneously delivered through the LCx. Animals received transgenes encoding a peptide inhibitor of βARK1 (Adeno-βARKct) or an empty virus (EV) as control. One week after gene delivery, global LV and regional systolic function were measured again to assess gene treatment. Adeno-βARKct delivery to the failing heart through the LCx resulted in chamber-specific expression of the βARKct. Baseline in vivo LV systolic performance was improved in Adeno-βARKct–treated animals compared with their individual pre–gene delivery values and compared with EV-treated rabbits. Total β-AR density and βARK1 levels were unchanged between treatment groups; however, β-AR–stimulated adenylyl cyclase activity in the LV was significantly higher in Adeno-βARKct–treated rabbits compared with EV-treated animals. Conclusions —In vivo delivery of Adeno-βARKct is feasible in the infarcted/failing heart by coronary catheterization; expression of βARKct results in marked reversal of ventricular dysfunction. Thus, inhibition of βARK1 provides a novel treatment strategy for improving the cardiac performance of the post-MI heart.
- 6 March 2001
- Published by Wolters Kluwer Health in Circulation
- Vol. 103 (9) , 1311-1316
In Vivo Ventricular Gene Delivery of a β-Adrenergic Receptor Kinase Inhibitor to the Failing Heart Reverses Cardiac Dysfunction
Background —Genetic manipulation to reverse molecular abnormalities associated with dysfunctional myocardium may provide novel treatment. This study aimed to determine the feasibility and functional consequences of in vivo β-adrenergic receptor kinase (βARK1) inhibition in a model of chronic left ventricular (LV) dysfunction after myocardial infarction (MI). Methods and Results —Rabbits underwent ligation of the left circumflex (LCx) marginal artery and implantation of sonomicrometric crystals. Baseline cardiac physiology was studied 3 weeks after MI; 5×10 11 viral particles of adenovirus was percutaneously delivered through the LCx. Animals received transgenes encoding a peptide inhibitor of βARK1 (Adeno-βARKct) or an empty virus (EV) as control. One week after gene delivery, global LV and regional systolic function were measured again to assess gene treatment. Adeno-βARKct delivery to the failing heart through the LCx resulted in chamber-specific expression of the βARKct. Baseline in vivo LV systolic performance was improved in Adeno-βARKct–treated animals compared with their individual pre–gene delivery values and compared with EV-treated rabbits. Total β-AR density and βARK1 levels were unchanged between treatment groups; however, β-AR–stimulated adenylyl cyclase activity in the LV was significantly higher in Adeno-βARKct–treated rabbits compared with EV-treated animals. Conclusions —In vivo delivery of Adeno-βARKct is feasible in the infarcted/failing heart by coronary catheterization; expression of βARKct results in marked reversal of ventricular dysfunction. Thus, inhibition of βARK1 provides a novel treatment strategy for improving the cardiac performance of the post-MI heart.
- 1 January 2001
- Published by Springer Nature in Current Cardiology Reports
- Vol. 3 (1) , 37-42
Myocardial gene transfer
Recent improvements in both gene transfer vectors and in vivo gene delivery techniques have facilitated genetic manipulation of myocardial function and enabled targeted therapy of animal models of cardiac disease and, in particular, heart failure. Increases in myocardial perfusion, improved calcium handling, and enhanced β-adrenergic receptor signaling have all been achieved by gene transfer in animal models, and appear to be important determinants of myocardial function. Increased understanding of the molecular etiologies of myocardial disease processes combined with advances in vectors and gene delivery will facilitate the development of novel therapies and represent important progress in the effort to make myocardial gene therapy a clinical reality beyond experimental protocols.
- 1 January 2001
- Published by Springer Nature in Current Cardiology Reports
- Vol. 3 (1) , 37-42
Myocardial gene transfer
Recent improvements in both gene transfer vectors and in vivo gene delivery techniques have facilitated genetic manipulation of myocardial function and enabled targeted therapy of animal models of cardiac disease and, in particular, heart failure. Increases in myocardial perfusion, improved calcium handling, and enhanced β-adrenergic receptor signaling have all been achieved by gene transfer in animal models, and appear to be important determinants of myocardial function. Increased understanding of the molecular etiologies of myocardial disease processes combined with advances in vectors and gene delivery will facilitate the development of novel therapies and represent important progress in the effort to make myocardial gene therapy a clinical reality beyond experimental protocols.